Atezolizumab plus nab-paclitaxel prolongs OS in PD-L1 IC–positive triple-negative breast cancer
21 Oct 2020
bởiDr Margaret Shi
A combined regimen of atezolizumab and nanoparticle albumin-bound (nab)-paclitaxel (A+nP) improves overall survival (OS) vs placebo plus nab-paclitaxel (P+nP) in patients with previously untreated, inoperable, locally advanced or metastatic, PD-L1 immune cell (IC)–positive triple-negative breast cancer (TNBC), according to the final analysis of the IMpassion130 study.